| P50 | author | Jesus Ruiz-Aragón | Q74777283 |
| P2093 | author name string | Ray Gani | |
| | Sergio Márquez | |
| | Piedad Alvarez | |
| P2860 | cites work | Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia. | Q30390901 |
| | Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients | Q30429017 |
| | An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model | Q35723417 |
| | Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain | Q37264948 |
| | Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe | Q37264984 |
| | Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model | Q37416216 |
| | Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies | Q38803189 |
| | Update: Influenza Activity - United States and Worldwide, May 21-September 23, 2017. | Q41923696 |
| | A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. | Q45778868 |
| | Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. | Q47150783 |
| | Estimating a cost-effectiveness threshold for the Spanish NHS. | Q47240643 |
| | Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain | Q49887147 |
| | Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. | Q51175571 |
| | Patients with influenza A (H1N1)pdm09 admitted to the ICU. Impact of the recommendations of the SEMICYUC. | Q52646313 |
| | Influenza epidemiology and influenza vaccine effectiveness during the 2015-2016 season: results from the Global Influenza Hospital Surveillance Network | Q64055452 |
| | Spanish recommendations on economic evaluation of health technologies | Q84078913 |
| | Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy | Q88512631 |
| | Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza | Q92360676 |
| | A review of the cost-effectiveness of adult influenza vaccination and other preventive services | Q92456759 |
| | Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season | Q92759311 |
| P921 | main subject | influenza vaccine | Q383260 |
| | cost-effectiveness analysis | Q1754768 |
| P304 | page(s) | 1-7 | |
| P577 | publication date | 2020-02-10 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain | |